Transferrin Receptor Identifies a Comprehensive Pool of Circulating Tumor Cells with Unique Molecular Features from Metastatic Prostate Cancer Patients

Abstract

T Metastatic castration resistant prostate cancer (CRPC) is currently incurable, due to treatment resistance. Elucidation of resistance mechanisms requires frequent tumor sampling to monitor tumor evolution and tailor treatments to the individual. Circulating tumor cells (CTCs) represent anon-invasive, accessible liquid biopsy source of tumor cells, allowing for longitudinal molecular disease profiling. Due to limitations with existing EpCAM based CTC isolation assays we have identified and clinically tested Transferrin Receptor (TfR) as a novel cell-surface antigen that enables capture of all CTCs across the EMT gradient from metastatic patients. Mining large datasets (TCGA, SU2C) revealed TfR enrichment in metastatic patients, which significantly correlated with advanced state from localized PC to CRPC to the aggressive neuroendocrine NEPC. RNA-seq analysis indicates that TfR+-CTCs possess unique expression profile and are enriched in EMT and tumor progression pathways, as compared to EpCAM+- CTCs.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2022
Accession Number
AD1200104

Entities

People

  • Paraskevi Giannakakou

Organizations

  • Cornell University

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Antigens
  • Biomedical Research
  • Blood
  • Cells
  • Disease Attributes
  • Diseases
  • Electronic Mail
  • Genes
  • Heterogeneity
  • Indirect Costs
  • Medical Personnel
  • Molecules
  • Neoplasms
  • New York
  • Prostate
  • Prostate Cancer
  • Proteins
  • Resistance

Fields of Study

  • Biology

Readers

  • Oncology
  • Oncology (Cancer Research).
  • Prostate Cancer Biology.